BioCentury
ARTICLE | Company News

PegBio, Pfizer form diabetes partnership in China

December 13, 2016 11:08 PM UTC

Pfizer Inc. (NYSE:PFE) granted PegBio Co. Ltd. (Suzhou, China) rights in Greater China to a glucokinase (GCK, GK) agonist to treat diabetes. The partnership is part of a Pfizer strategy to use local partners to advance medicines addressing unmet needs. The partners did not respond to inquiries about the program.

PegBio said financial terms were not disclosed and that the GCK program has completed Phase IIa development...

BCIQ Company Profiles

PegBio Co. Ltd.

Pfizer Inc.

BCIQ Target Profiles

Glucokinase (GCK) (GK)